Mark Eric Layton - Publications

Affiliations: 
2002 Harvard University, Cambridge, MA, United States 

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

PUBLICATION UPDATES TEMPORARILY DISABLED DURING DATABASE UPDATE, SORRY!

Year Citation  Score
2016 Pero JE, Rossi MA, Kelly MJ, Lehman HD, Layton ME, Garbaccio RM, O'Brien JA, Magliaro BC, Uslaner JM, Huszar SL, Fillgrove KL, Tang C, Kuo Y, Joyce LA, Sherer EC, et al. Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. Acs Medicinal Chemistry Letters. 7: 312-7. PMID 26985321 DOI: 10.1021/acsmedchemlett.5b00459  0.56
2016 Layton ME, Reif AJ, Hartingh TJ, Rodzinak K, Dudkin V, Wang C, Arrington K, Kelly MJ, Garbaccio RM, O'Brien JA, Magliaro BC, Uslaner JM, Huszar SL, Fillgrove KL, Tang C, et al. Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis. Bioorganic & Medicinal Chemistry Letters. PMID 26810316 DOI: 10.1016/j.bmcl.2016.01.021  0.56
2011 Layton ME, Kelly MJ, Rodzinak KJ, Sanderson PE, Young SD, Bednar RA, Dilella AG, McDonald TP, Wang H, Mosser SD, Fay JF, Cunningham ME, Reiss DR, Fandozzi C, Trainor N, et al. Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists. Acs Chemical Neuroscience. 2: 352-62. PMID 22816022 DOI: 10.1021/cn200013d  0.56
2010 Brnardic EJ, Fraley ME, Garbaccio RM, Layton ME, Sanders JM, Culberson C, Jacobson MA, Magliaro BC, Hutson PH, O'Brien JA, Huszar SL, Uslaner JM, Fillgrove KL, Tang C, Kuo Y, et al. 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. Bioorganic & Medicinal Chemistry Letters. 20: 3129-33. PMID 20409708 DOI: 10.1016/j.bmcl.2010.03.089  0.56
2008 Lindsley CW, Barnett SF, Layton ME, Bilodeau MT. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Current Cancer Drug Targets. 8: 7-18. PMID 18288939 DOI: 10.2174/156800908783497096  0.56
2007 Lindsley CW, Barnett SF, Yaroschak M, Bilodeau MT, Layton ME. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Current Topics in Medicinal Chemistry. 7: 1349-63. PMID 17692025 DOI: 10.2174/156802607781696864  0.56
2006 Layton ME, Kelly MJ, Rodzinak KJ. Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Current Topics in Medicinal Chemistry. 6: 697-709. PMID 16719810 DOI: 10.2174/156802606776894447  0.56
2005 Layton ME. Subtype-selective noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1). Current Topics in Medicinal Chemistry. 5: 859-67. PMID 16178731 DOI: 10.2174/1568026054750245  0.56
2004 Morales CA, Layton ME, Shair MD. Synthesis of (-)-longithorone A: using organic synthesis to probe a proposed biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 101: 12036-41. PMID 15190180 DOI: 10.1073/pnas.0401952101  1
2002 Layton ME, Morales CA, Shair MD. Biomimetic synthesis of (-)-longithorone A. Journal of the American Chemical Society. 124: 773-5. PMID 11817951 DOI: 10.1021/ja016585u  1
2000 Aloise AD, Layton ME, Shair MD. Synthesis of cyclooctenones using intramolecular hydroacylation Journal of the American Chemical Society. 122: 12610-12611. DOI: 10.1021/ja0055920  1
2000 Chen C, Layton ME, Sheehan SM, Shair MD. Synthesis of (+)-CP-263,114 [20] Journal of the American Chemical Society. 122: 7424-7425. DOI: 10.1021/ja001958x  1
1998 Chen C, Layton ME, Shair MD. Stereospecific synthesis of the CP-263,114 core structure [13] Journal of the American Chemical Society. 120: 10784-10785. DOI: 10.1021/ja982581m  1
Show low-probability matches.